Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with few treatment options.
Ruxolitinib in CMML: Study Shows Promising Results
Recent Articles
Identifying Causes of Cardiomyopathy in Patients With Sickle Cell Anemia
Author’s Perspective
Lead author Omar Niss, MD: “Diffuse myocardial fibrosis is a common finding and a newly recognized mechanism of heart disease in sickle cell...
FDA Calls for Manufacturer to Pull Opioid from the Market
The U.S. Food and Drug Administration (FDA) has called for Endo Pharmaceuticals to remove its reformulation of oxymorphone hydrochloride extended-release, Opana ER, because of...
Legislators Propose Two Bills to Lower Drug Prices
Both Democrats and Republicans have introduced bills aimed to lower prescription drug prices: One would renew the U.S. Food and Drug Administration’s (FDA) authority...
NIH No Longer Considering Capping Grants for Individual Labs
In May, the National Institutes of Health (NIH) proposed restricting the amount of funding that an individual laboratory could hold in order to free...
July 2017, Volume 3, Issue 8
This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.
Current Issue
July 2017, Volume 3, Issue 8
This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.
